• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Agilent Technologies (A) Is Up 5.4% After New OPDIVO-Linked PD-L1 Test Approval - Has The Bull Case Changed?

    Simply Wall St·07/26/2026 21:21:21
    Listen to the news
    • In July 2026, Agilent Technologies received U.S. FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG immunotherapies, for use exclusively on the Agilent Autostainer Link 48 platform.
    • This decision deepens Agilent’s role in oncology testing by tying its assay and staining system directly to established immunotherapy regimens in cancer types with high global mortality and limited long-term survival.
    • We’ll now examine how this new FDA-approved companion diagnostic for OPDIVO-linked therapies may reshape Agilent’s investment narrative in oncology diagnostics.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    Agilent Technologies Investment Narrative Recap

    To own Agilent, you generally need to believe in steady demand for lab instruments and diagnostics, rising recurring revenue, and disciplined cost control. The new PD-L1 28-8 FDA approval strengthens Agilent’s oncology testing credentials, but its impact on near term results likely remains incremental compared with broader pharma and industrial demand, while competitive intensity and tariff driven margin pressure still stand out as key risks.

    The most connected recent development is Agilent’s earlier FDA approval of the PD-L1 22C3 pharmDx assay for KEYTRUDA across several cancer indications. Together, these approvals broaden Agilent’s role as a biomarker testing partner in immuno oncology, reinforcing the catalyst around higher margin, recurring diagnostics and consumables that complement its core analytical instrument replacement cycles.

    Yet against this progress, investors should also be aware that rising tariffs and supply chain complexity could still...

    Read the full narrative on Agilent Technologies (it's free!)

    Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029. This requires 6.7% yearly revenue growth and a roughly $0.7 billion earnings increase from $1.4 billion today.

    Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 16% upside to its current price.

    Exploring Other Perspectives

    A 1-Year Stock Price Chart
    A 1-Year Stock Price Chart

    Four fair value estimates from the Simply Wall St Community cluster between US$150.54 and US$177.28, showing how far individual views can stretch. You can weigh those against the oncology focused companion diagnostic approvals that may influence Agilent’s mix of recurring diagnostics revenue over time and consider how different assumptions about margins and funding trends could shape the company’s path.

    Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth just $150.54!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

    Contemplating Other Strategies?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.